JP5767116B2 - 白金に基づく治療に対する応答の予測 - Google Patents

白金に基づく治療に対する応答の予測 Download PDF

Info

Publication number
JP5767116B2
JP5767116B2 JP2011549604A JP2011549604A JP5767116B2 JP 5767116 B2 JP5767116 B2 JP 5767116B2 JP 2011549604 A JP2011549604 A JP 2011549604A JP 2011549604 A JP2011549604 A JP 2011549604A JP 5767116 B2 JP5767116 B2 JP 5767116B2
Authority
JP
Japan
Prior art keywords
rbm3
cancer
sample
protein
platinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011549604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012518164A (ja
JP2012518164A5 (https=
Inventor
カリン・イルストレム
ヤコブ・エーベルハルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlas Antibodies AB
Original Assignee
Atlas Antibodies AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/SE2009/000091 external-priority patent/WO2009102261A1/en
Priority claimed from EP09158084A external-priority patent/EP2241889A1/en
Priority claimed from EP09167847A external-priority patent/EP2293070A1/en
Application filed by Atlas Antibodies AB filed Critical Atlas Antibodies AB
Publication of JP2012518164A publication Critical patent/JP2012518164A/ja
Publication of JP2012518164A5 publication Critical patent/JP2012518164A5/ja
Application granted granted Critical
Publication of JP5767116B2 publication Critical patent/JP5767116B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2011549604A 2009-02-16 2010-02-16 白金に基づく治療に対する応答の予測 Expired - Fee Related JP5767116B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
PCT/SE2009/000091 WO2009102261A1 (en) 2008-02-15 2009-02-16 Rbm3 as a marker for breast cancer prognosis
SEPCT/SE2009/000091 2009-02-16
US16996309P 2009-04-16 2009-04-16
EP09158084A EP2241889A1 (en) 2009-04-16 2009-04-16 RBM3 protein in colorectal cancer prognostics
EP09158084.5 2009-04-16
US61/169,963 2009-04-16
US23376909P 2009-08-13 2009-08-13
EP09167847.4 2009-08-13
US61/233,769 2009-08-13
EP09167847A EP2293070A1 (en) 2009-08-13 2009-08-13 Means and methods for ovarian cancer prognosis
EPPCT/EP2009/067419 2009-12-17
PCT/EP2009/067419 WO2010091763A1 (en) 2009-02-16 2009-12-17 Rbm3 as a marker for malignant melanoma prognosis
PCT/EP2010/051941 WO2010092190A2 (en) 2009-02-16 2010-02-16 Prediction of response to platinum-based therapy

Publications (3)

Publication Number Publication Date
JP2012518164A JP2012518164A (ja) 2012-08-09
JP2012518164A5 JP2012518164A5 (https=) 2013-04-04
JP5767116B2 true JP5767116B2 (ja) 2015-08-19

Family

ID=41718882

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011549604A Expired - Fee Related JP5767116B2 (ja) 2009-02-16 2010-02-16 白金に基づく治療に対する応答の予測
JP2011549601A Expired - Fee Related JP5611986B2 (ja) 2009-02-16 2010-02-16 結腸直腸癌の予後診断におけるｒｂｍ３タンパク質
JP2011549603A Expired - Fee Related JP5669757B2 (ja) 2009-02-16 2010-02-16 精巣癌診断および予後診断におけるｒｂｍ３タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011549601A Expired - Fee Related JP5611986B2 (ja) 2009-02-16 2010-02-16 結腸直腸癌の予後診断におけるｒｂｍ３タンパク質
JP2011549603A Expired - Fee Related JP5669757B2 (ja) 2009-02-16 2010-02-16 精巣癌診断および予後診断におけるｒｂｍ３タンパク質

Country Status (8)

Country Link
US (3) US8632984B2 (https=)
EP (4) EP2396657B1 (https=)
JP (3) JP5767116B2 (https=)
CN (1) CN102334032B (https=)
AU (4) AU2009339802B2 (https=)
CA (3) CA2749349A1 (https=)
DK (2) DK2396659T3 (https=)
WO (5) WO2010091763A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2396657B1 (en) * 2009-02-16 2013-11-13 Atlas Antibodies AB Rbm3 as a marker for malignant melanoma prognosis
EP2524928A1 (en) 2011-05-18 2012-11-21 Atlas Antibodies AB RBM3 in bladder cancer
CA2818593A1 (en) * 2010-10-22 2012-04-26 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
US20120288480A1 (en) * 2011-02-22 2012-11-15 Taipei Medical University Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications
EP2573566A1 (en) * 2011-09-20 2013-03-27 Atlas Antibodies AB RBM3 in prostate cancer prognostics
CN102590185B (zh) * 2012-01-11 2013-12-25 东南大学 以适体为识别单元的胶体晶体凝胶非标记可视化检测方法
WO2016004387A1 (en) * 2014-07-02 2016-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene expression signature for cancer prognosis
EP3023791A1 (en) * 2014-11-21 2016-05-25 Atlas Antibodies AB Predicting the responsiveness to gemcitabine treatment
CN106611094B (zh) * 2015-10-15 2021-08-06 北京寻因生物科技有限公司 基于肠道微生物菌群预测及干预化疗药物毒副反应的系统
CN113373151B (zh) * 2021-06-30 2022-05-03 华中科技大学同济医学院附属协和医院 环状RNAhsa_circ_0008399的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
GB9917027D0 (en) 1999-07-20 1999-09-22 Affibody Technology Sweeden Ab In vitro selection and optional identification of polypeptides using solid support carriers
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
WO2006071896A2 (en) * 2004-12-23 2006-07-06 The Hong Kong University Of Science And Technology Epitope-based sars vaccine
EP1934867A2 (en) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2007084485A2 (en) 2006-01-13 2007-07-26 Battelle Memorial Institute Markers for assessing copd-related diseases
EP1862803A1 (en) * 2006-06-02 2007-12-05 Atlas Antibodies AB Use of protein SATB2 as a marker for colorectal cancer
EP2090890A1 (en) * 2008-02-15 2009-08-19 Atlas Antibodies AB RBM3 as a marker for breast cancer prognosis
US7902166B2 (en) * 2008-04-03 2011-03-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
EP2396657B1 (en) * 2009-02-16 2013-11-13 Atlas Antibodies AB Rbm3 as a marker for malignant melanoma prognosis
EP2524928A1 (en) * 2011-05-18 2012-11-21 Atlas Antibodies AB RBM3 in bladder cancer

Also Published As

Publication number Publication date
WO2010091763A1 (en) 2010-08-19
EP2396657A1 (en) 2011-12-21
JP2012518163A (ja) 2012-08-09
EP2396659A1 (en) 2011-12-21
EP2396346B1 (en) 2013-04-03
CA2749392A1 (en) 2010-08-19
AU2010212772A1 (en) 2011-07-28
EP2396660A2 (en) 2011-12-21
EP2396659B1 (en) 2012-11-21
AU2009339802A1 (en) 2011-07-28
CN102334032A (zh) 2012-01-25
HK1166371A1 (en) 2012-10-26
JP5669757B2 (ja) 2015-02-18
CA2749349A1 (en) 2010-08-19
CN102334032B (zh) 2015-01-28
AU2010212769B2 (en) 2014-07-17
EP2396660B1 (en) 2013-07-24
WO2010092190A2 (en) 2010-08-19
JP2012518164A (ja) 2012-08-09
AU2010212772B2 (en) 2014-07-17
JP5611986B2 (ja) 2014-10-22
DK2396659T3 (da) 2013-03-04
US8747910B2 (en) 2014-06-10
WO2010092187A1 (en) 2010-08-19
AU2010212769C1 (en) 2014-10-09
AU2009339802B2 (en) 2014-07-24
US20120058202A1 (en) 2012-03-08
EP2396657B1 (en) 2013-11-13
US20120269764A1 (en) 2012-10-25
US20120034317A1 (en) 2012-02-09
AU2010212764B2 (en) 2014-07-17
EP2396346A1 (en) 2011-12-21
WO2010092190A3 (en) 2010-11-04
WO2010092182A1 (en) 2010-08-19
AU2010212769A1 (en) 2011-07-28
US8632984B2 (en) 2014-01-21
DK2396660T3 (da) 2013-10-28
JP2012518162A (ja) 2012-08-09
CA2749350A1 (en) 2010-08-19
AU2010212764A1 (en) 2011-07-28
WO2010092184A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
AU2010311540B9 (en) PODXL protein in colorectal cancer
JP5767116B2 (ja) 白金に基づく治療に対する応答の予測
US9416176B2 (en) RBM3 protein in colorectal cancer prognostics
EP2293070A1 (en) Means and methods for ovarian cancer prognosis
EP2602622A1 (en) Prediction of response to platinum-based therapy
US20160054324A1 (en) Asrgl1 in endometrial cancer
EP2241889A1 (en) RBM3 protein in colorectal cancer prognostics
HK1166371B (en) Prediction of response to platinum-based therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150618

R150 Certificate of patent or registration of utility model

Ref document number: 5767116

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees